Developing and sustaining India's capacity for preclinical drug discovery
Indian J Pharmacol
.
2018 Sep-Oct;50(5):225-226.
doi: 10.4103/ijp.IJP_641_18.
Authors
David I Lewis
1
,
Bhagirath K Patel
2
,
B Dinesh Kumar
3
,
Bikash Medhi
4
Affiliations
1
School of Biomedical Sciences (Faculty of Biological Sciences), University of Leeds, Leeds, UK.
2
Director of Sat Kaival College of Pharmacy (SKCOP), General Secretary, Indian Pharmacological Society (IPS), Sarsa, Gujarat, India.
3
Drug Toxicology Division, National Institute of Nutrition, Hyderabad, India.
4
Department of Pharmacology, PGIMER, Chandigarh, India.
PMID:
30636824
PMCID:
PMC6302698
DOI:
10.4103/ijp.IJP_641_18
No abstract available
Publication types
Editorial
MeSH terms
Animals
Drug Development / methods*
Drug Discovery / methods*
Drug Evaluation, Preclinical / methods*
Humans
India